Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-12T19:56:13.491Z Has data issue: false hasContentIssue false

Chapter 35 - Hematopoietic Cell Transplants for Myelodysplastic Syndromes

from Section 10 - Hematopoietic Cell Transplants for Acute Leukemia and Myelodysplastic Syndrome

Published online by Cambridge University Press:  24 May 2017

By
Natasha Kekre ,
R. Coleman Lindsley  and
John Koreth
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 328 - 338
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cogle, CR, Craig, BM, Rollison, DE, List, AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–5.CrossRefGoogle ScholarPubMed
Greenberg, P, Cox, C, LeBeau, MM, Fenaux, P, Morel, P, Sanz, G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–88.CrossRefGoogle ScholarPubMed
Malcovati, L, Germing, U, Kuendgen, A, Della Porta, MG, Pascutto, C, Invernizzi, R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007;25(23):3503–10.CrossRefGoogle ScholarPubMed
Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.CrossRefGoogle ScholarPubMed
Estey, E, de Lima, M, Tibes, R, Pierce, S, Kantarjian, H, Champlin, R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395–400.CrossRefGoogle Scholar
McClune, BL, Weisdorf, DJ, Pedersen, TL, Tunes da Silva, G, Tallman, MS, Sierra, J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(11):1878–87.CrossRefGoogle ScholarPubMed
Pasquini, MC, Wang, Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. Updated 2013. Available from: www.cibmtr.org.Google Scholar
Park, S, Grabar, S, Kelaidi, C, Beyne-Rauzy, O, Picard, F, Bardet, V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574–82.CrossRefGoogle ScholarPubMed
Fenaux, P, Mufti, GJ, Hellstrom-Lindberg, E, Santini, V, Finelli, C, Giagounidis, A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet Oncology. 2009;10(3):223–32.CrossRefGoogle ScholarPubMed
Lubbert, M, Suciu, S, Baila, L, Ruter, BH, Platzbecker, U, Giagounidis, A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(15):1987–96.CrossRefGoogle ScholarPubMed
Greenberg, PL, Attar, E, Bennett, JM, Bloomfield, CD, De Castro, CM, Deeg, HJ, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network: JNCCN. 2011;9(1):30–56.CrossRefGoogle ScholarPubMed
Prebet, T, Gore, SD, Esterni, B, Gardin, C, Itzykson, R, Thepot, S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(24):3322–7.CrossRefGoogle ScholarPubMed
de Witte, T, Hermans, J, Vossen, J, Bacigalupo, A, Meloni, G, Jacobsen, N, et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). British Journal of Haematology. 2000;110(3):620–30.CrossRefGoogle Scholar
Brand, R, Putter, H, van Biezen, A, Niederwieser, D, Martino, R, Mufti, G, et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One. 2013;8(10):e74368.CrossRefGoogle Scholar
Platzbecker, U, Schetelig, J, Finke, J, Trenschel, R, Scott, BL, Kobbe, G, et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(9):1415–21.CrossRefGoogle ScholarPubMed
Robin, M, Porcher, R, Ades, L, Raffoux, E, Michallet, M, Francois, S, et al. Outcome of patients with IPSS intermediate (int) or high risk myelodysplastic syndrome (MDS) according to donor availability: a multicenter prospective non interventional study for the SFGM-TC and GFM. Blood. 2013;122(301).CrossRefGoogle Scholar
Cutler, CS, Lee, SJ, Greenberg, P, Deeg, HJ, Perez, WS, Anasetti, C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–85.CrossRefGoogle ScholarPubMed
Alessandrino, EP, Porta, MG, Malcovati, L, Jackson, CH, Pascutto, C, Bacigalupo, A, et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology. 2013;88(7):581–8.CrossRefGoogle ScholarPubMed
Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(21):2662–70.CrossRefGoogle ScholarPubMed
Della Porta, MG, Alessandrino, EP, Bacigalupo, A, van Lint, MT, Malcovati, L, Pascutto, C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123(15):2333–42.CrossRefGoogle Scholar
Hahn, T, McCarthy, PL Jr., Hassebroek, A, Bredeson, C, Gajewski, JL, Hale, GA, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013;31(19):2437–49.CrossRefGoogle ScholarPubMed
Brunner, AM, Kim, HT, Coughlin, E, Alyea, EP, 3rd, Armand, P, Ballen, KK, et al. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(9):1374–80.CrossRefGoogle ScholarPubMed
Luger, SM, Ringden, O, Zhang, MJ, Perez, WS, Bishop, MR, Bornhauser, M, et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplantation. 2012;47(2):203–11.CrossRefGoogle ScholarPubMed
Martino, R, de Wreede, L, Fiocco, M, van Biezen, A, von dem Borne, PA, Hamladji, RM, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplantation. 2013;48(6):761–70.CrossRefGoogle ScholarPubMed
Chen, YB, Coughlin, E, Kennedy, KF, Alyea, EP, Armand, P, Attar, EC, et al. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2013;19(6):981–7.CrossRefGoogle ScholarPubMed
Soiffer, RJ, Lerademacher, J, Ho, V, Kan, F, Artz, A, Champlin, RE, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963–70.CrossRefGoogle ScholarPubMed
Finke, J, Bethge, WA, Schmoor, C, Ottinger, HD, Stelljes, M, Zander, AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. The Lancet Oncology. 2009;10(9):855–64.CrossRefGoogle ScholarPubMed
Kroger, N, Zabelina, T, de Wreede, L, Berger, J, Alchalby, H, van Biezen, A, et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia. 2013;27(3):604–9.CrossRefGoogle ScholarPubMed
Saber, W, Cutler, CS, Nakamura, R, Zhang, MJ, Atallah, E, Rizzo, JD, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013;122(11):1974–82.CrossRefGoogle ScholarPubMed
Kim, Y, Kim, IH, Kim, HJ, Park, S, Lee, KH, Kim, SJ, et al. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. International Journal of Hematology. 2014;99(5):635–43.CrossRefGoogle ScholarPubMed
Damaj, G, Duhamel, A, Robin, M, Beguin, Y, Michallet, M, Mohty, M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(36):4533–40.CrossRefGoogle ScholarPubMed
Gerds, AT, Gooley, TA, Estey, EH, Appelbaum, FR, Deeg, HJ, Scott, BL. Pretransplantation therapy with azacitidine vs induction chemotherapy and post-transplantation outcome in patients with MDS. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2012;18(8):1211–8.CrossRefGoogle Scholar
Pollyea, DA, Artz, AS, Stock, W, Daugherty, C, Godley, L, Odenike, OM, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 2007;40(11):1027–32.CrossRefGoogle ScholarPubMed
Schroeder, T, Czibere, A, Platzbecker, U, Bug, G, Uharek, L, Luft, T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229–35.Google ScholarPubMed
Platzbecker, U, Wermke, M, Radke, J, Oelschlaegel, U, Seltmann, F, Kiani, A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–9.CrossRefGoogle ScholarPubMed
de Lima, M, Giralt, S, Thall, PF, de Padua, Silva L, Jones, RB, Komanduri, K, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010;116(23):5420–31.CrossRefGoogle ScholarPubMed
Goodyear, OC, Dennis, M, Jilani, NY, Loke, J, Siddique, S, Ryan, G, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119(14):3361–9.CrossRefGoogle ScholarPubMed
Ho, VT, Vanneman, M, Kim, H, Sasada, T, Kang, YJ, Pasek, M, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(37):15825–30.Google ScholarPubMed
Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–7.CrossRefGoogle ScholarPubMed
Papaemmanuil, E, Gerstung, M, Malcovati, L, Tauro, S, Gundem, G, Van Loo, P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27; quiz 99.CrossRefGoogle ScholarPubMed
Bejar, R, Stevenson, K, Abdel-Wahab, O, Galili, N, Nilsson, B, Garcia-Manero, G, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine. 2011;364(26):2496–506.CrossRefGoogle ScholarPubMed
Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012;30(27):3376–82.CrossRefGoogle ScholarPubMed
Bejar, R. Prognostic models in myelodysplastic syndromes. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2013;2013:504–10.Google ScholarPubMed
Bejar, R, Stevenson, KE, Caughey, B, Lindsley, RC, Mar, BG, Stojanov, P, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32(25):2691–8.CrossRefGoogle ScholarPubMed
Deeg, HJ, Scott, BL, Fang, M, Shulman, HM, Gyurkocza, B, Myerson, D, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120(7):1398–408.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×